Drug Trial Radar · NCT07944625
Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
414
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Aug 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Interlude Biopharma Co.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.
Conditions
- Celiac Disease
- Celiac Disease in Adolescents
Interventions
Larazotide AcetateDrug
Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.
PlaceboDrug
Placebo capsules will be taken orally TID for 14 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of responders treatment with larazotide acetate (0.25 mg or 0.5 mg) compared to placebo during the last two weeks of the 14-week treatment periodTime frame: Last two weeks of the treatment period (Weeks 13-14)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.